



The Nifty ended 1.36% up at 14,504.80. It opened on a positive note and remained extremely choppy in the first half, however, sharp up move in the second half helped the benchmark index closing with a bullish candle. Candle pattern suggests the benchmark index moving higher towards critical resistance placed around 14,650 is the most likely. Midway resistance is placed around 14,530 levels. 14,400 is the immediate support, while the broader trading range is likely to be 14,650 -14,300.

On the Nifty hourly chart; Oversold leading indicators turned upwards following the sharp up move, however, the ADX is still pointing towards range bound oscillation in coming sessions. Probable trading range is likely to be 14,650-14,300.

Nifty patterns on multiple time frames suggest; turning around from the oversold zone and ending with a decent gain is a sign of continuation of current pullback rally. 14,650 is the immediate resistance.

### Nifty Crucial Supports & Resistances-

**Supports- 14400, 14300 Resistances- 14530, 14650**

### Open Positional Calls-

T+5 Positional Sell-

|Futures Segment| SAIL Fut @ 91-92, TGT- 82, SL- above 97

T+5 Positional Buy-

|Cash Segment| KOTAK BANK @ 1725-1720, TGT- 1810, Closing SL- 1670

T+5 Positional Buy-

|Cash Segment| HDFC BANK @ 1370-1360, TGT- 1430, Closing SL- 1320

T+3 Positional Buy-

|Cash Segment| LUPIN @ 1060-1050, TGT- 1110, Closing SL- 1020

T+5 Positional Buy-

|Cash Segment| RIL @ 1905-1900, TGT- 1980, Closing SL- 1860

T+5 Positional Buy-

|Cash Segment| CADILA @ 485-480, TGT- 520, Closing SL- 460

T+2 Positional Buy-

|Cash Segment| SUN PHARMA @ 627-625, TGT- 645, Closing SL- 615

Key Contents	Page No.
Result Update	4
Domestic News	5

## Nifty Intraday Chart



## Market in Retrospect

Indian equities saw a rebound from two-month lows after a bout of short covering took the indices higher from lower levels.

NIFTY index ended 1.36% higher at 14,505. The broader markets represented by the NIFTY 500 Index ended 1.35% higher, ending at 12,187. Among the sectorial indices, NIFTY PSU Bank was the top gainer, gaining by 4.49%, followed by NIFTY Auto, gaining by 4.28% higher. NIFTY IT was the top loser, losing by 3.28%.

M&M was the top gainer, gaining by 7.95%, followed by Bajaj Finserv and Tata Motors which gained by 7.02% & 5.69% respectively. Dr. Reddy's was the top loser, losing by 4.40%, followed by TCS and Tech Mahindra, which fell by 4.10% & 3.05% respectively.

The Advance: Decline ratio stood at 1386:507

### Market Turnover (In Crore) 13-04-2021

Name	Last	Previous
NSE Cash	*NA	84028.72
NSE F&O	4292923.97	3535508.06
BSE Cash	3,993.06	5,780.15
BSE F&O	*NA	136.60

### FII Derivatives Flow (In Crore) 12-04-2021\*

Instrument	Purchase	Sale	Net
Index Future	6192.96	7933.41	1740.45
Index Option	412371.39	410417.31	1954.08
Stock Future	17189.34	17587.33	397.99
Stock Option	20690.02	21265.16	575.14

### Institutional Flow (In Crore) 12-04-2021\*

Institution	Purchase	Sale	Net
FII	6519.91	8266.34	1746.43
DII	7165.01	6932.25	232.76

\*Data not updated till 5.35pm

### NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
M&M	7.95	3.86	12501628	3054660
Bajaj Finserv	7.02	3.02	830915	378659
Tata Motors	5.69	1.59	116874853	69074130
Bajaj Finance	4.83	5.29	3175019	2656852
Maruti Suzuki	4.53	0.96	995718	698601

### NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
HCL	2.58	4.38	7773994	4469588
Wipro	3.16	1.92	20420320	12378090
Tech Mahindra	3.65	1.06	6448995	5206680
TCS	4.39	4.92	8654596	2812781
Dr. Reddy'S Lab	4.40	3.42	3937234	1478491

### Bulk and Block Deals

<https://www.nseindia.com/products/content/Equities/equities/bulk.htm>  
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

## Sensex Intraday Chart



## Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	48544.06	660.68	1.38	1.34	4.43	2.10	58.18
Nifty	14504.80	194.00	1.36	1.22	3.50	0.62	61.27
BSE M Cap	19943.99	287.23	1.46	2.64	3.08	4.49	77.00
BSE S Cap	20805.48	248.47	1.21	1.02	1.90	10.37	103.05
Nifty MC 100	23516.85	402.70	1.74	2.08	2.48	6.15	90.02
BSE Auto	22136.99	912.93	4.30	0.54	5.60	3.88	79.28
BSE Capgoods	20506.11	404.58	2.01	2.67	7.82	4.38	76.42
BSE FMCG	12867.42	65.06	0.51	0.46	5.21	1.08	20.19
BSE Metal	15778.85	535.29	3.51	2.39	13.75	24.99	150.76
BSE Oil&Gas	14576.28	304.31	2.13	1.49	8.27	3.59	33.37
BSE Healthcare	22399.82	150.83	0.67	2.16	5.23	1.52	51.65
BSE Power	2399.14	38.67	1.64	5.76	4.57	12.84	67.32
BSE Realty	2502.34	65.74	2.70	3.99	10.15	6.19	84.64
BSE ConsDur	31923.40	130.42	0.41	0.32	4.10	4.18	58.99
BSE Bank	36088.53	1120.70	3.20	1.73	9.77	2.40	61.01
BSE IT	26743.10	721.36	2.63	2.27	1.75	0.52	111.21

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.68	0.01	0.86	1.46	3.41	55.11	117.83
UK	0.80	0.01	0.76	0.25	3.29	158.96	159.80
Brazil	4.25	0.04	0.95	0.35	0.81	20.55	1.19
Japan	0.11	0.00	0.93	5.31	13.01	167.50	365.22
Australia	1.81	0.04	2.09	1.57	6.22	63.65	99.12
India	6.01	0.01	0.10	1.15	3.55	1.57	7.38
Switzerland	0.24	0.01	2.04	17.24	3.90	46.07	23.08
Germany	0.28	0.01	3.41	10.44	7.52	45.79	18.44

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	75.06	0.31	0.41	2.34	3.02	2.40	1.63
USD Index	92.25	0.11	0.12	0.09	0.63	2.10	7.14
YUAN	6.55	0.00	0.01	0.15	0.75	1.24	7.67
GBP	1.37	0.00	0.15	0.75	1.29	0.60	9.64
EUR	1.19	0.00	0.18	0.12	0.33	2.20	8.94
YEN	109.31	0.07	0.06	0.40	0.16	4.96	1.41

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2145.00	60.00	2.88	2.53	9.44	15.57	237.80
Baltic Dirty	629.00	17.00	2.63	8.18	12.76	25.80	43.54
SG Dubai HY	0.88	0.18	25.71	25.71	2100.00	49.15	53.19

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	33745.40	55.20	0.16	0.65	2.95	8.64	44.27
Nasdaq	13850.00	50.19	0.36	1.05	3.98	5.49	69.06
S&P 500	4127.99	0.81	0.02	1.23	4.68	8.35	49.48
FTSE100	6878.47	10.30	0.15	0.81	1.74	1.98	17.73
CAC40	6177.86	16.18	0.26	0.76	2.17	9.10	37.08
DAX	15237.98	22.15	0.15	0.16	5.07	9.31	44.23
Mexico IPC	47352.18	275.49	0.58	1.85	0.87	3.52	36.80
Brazil Bovespa	118811.7	1141.80	0.97	1.10	4.07	2.56	50.71
Russian RTS	1433.81	1.33	0.09	0.49	5.64	3.56	27.45
Japan Nikkei	29751.61	212.88	0.72	0.19	0.11	3.67	51.49
Hang Seng	28497.25	43.97	0.15	1.53	0.84	0.00	16.62
Taiwan Index	16824.91	34.79	0.21	0.51	3.50	7.12	62.83
Shanghai Comp	3396.47	16.48	0.48	2.48	1.64	4.75	20.13
KOSPI	3169.08	33.49	1.07	1.34	3.75	0.61	70.65
Malaysia KLCI	1597.71	10.71	0.67	1.19	1.11	2.32	16.48
Jakarta Comp	5927.43	21.13	0.36	1.26	6.78	7.79	25.94
Philippine SE	6457.79	60.85	0.93	0.58	4.02	11.21	11.71
Thai Exch	1541.12	25.22	1.61	3.45	1.73	0.40	24.61

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	59.98	0.29	0.49	1.11	8.57	13.38	167.69
BRENT Crude	63.67	0.38	0.60	1.47	7.31	14.19	53.92
Natural Gas	2.54	0.02	0.86	3.38	3.68	6.21	2.67

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1727.98	4.93	0.28	0.89	0.04	6.38	0.73
Silver(\$/Ounce)	24.95	0.13	0.54	0.84	3.74	1.08	61.86
Aluminium	2245.50	1.25	0.06	1.93	4.60	11.25	55.88
Copper	8864.25	71.00	0.79	0.79	2.63	11.30	77.53
Zinc	2734.45	73.55	2.62	0.82	1.72	0.77	44.93
Lead	1954.35	1.90	0.10	0.66	0.93	2.34	14.76

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	129.00	1.00	0.77	0.23	4.41	0.12	2.22
Cotton	80.30	0.14	0.17	1.12	4.63	4.56	42.22
Sugar	15.42	0.06	0.39	2.59	1.91	6.57	33.85
Wheat	634.00	2.75	0.44	3.47	0.32	2.08	13.26
Soybean	1386.50	4.50	0.33	2.27	1.89	1.23	60.75

### **Tata Consultancy Services**

Tata Consultancy Services (TCS) kick started the earnings season by reporting a 14.9% rise in net profit at INR9,246 crore for the quarter ended March, 2021 as compared to INR8,049 crore in the same quarter last year. The company's revenue grew 9.4% to INR43,705 crore from INR39,946 crore in the corresponding period last fiscal. The company's constant currency growth came at 4.2% quarter-on-quarter (QoQ) and 5.9% YoY. The operating margin in the fourth quarter (Q4) was reported at 26.8%, 0.2% expansion QoQ and 1.7% YoY. The company said that the board have recommended a Final Dividend of INR15 per equity share. The company said its net addition is at 19,388 employees, highest ever in a quarter. For the quarter ending December 2020, TCS' net profit came at INR8,701 crore while the revenue stood at INR42,015 crore. TCS' revenue from its largest vertical i.e., Banking, Financial Services and Insurance (BFSI) came at INR17,559 crore, up 15% against INR15,207 crore year-on-year (YoY). Its Q4 Order Book stands at \$9.2 billion; highest ever TCV in a quarter.

### **Lloyds Metals & Energy**

Net profit of Lloyds Metals & Energy declined 74.81% to INR5.35 crore in the quarter ended March 2021 as against INR21.24 crore during the previous quarter ended March 2020. Sales declined 8.41% to INR95.24 crore in the quarter ended March 2021 as against INR103.99 crore during the previous quarter ended March 2020. For the full year, net profit declined 99.59% to INR0.13 crore in the year ended March 2021 as against INR31.83 crore during the previous year ended March 2020. Sales declined 31.83% to INR253.41 crore in the year ended March 2021 as against INR371.74 crore during the previous year ended March 2020.

### Dr Reddy's receives DCGI approval for COVID-19 vaccine Sputnik for restricted emergency use

Dr Reddy's Laboratories on Tuesday said it has received approval from Indian drug regulator for restricted emergency use of COVID-19 vaccine Sputnik in the country. The company has received the permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act. In September 2020, Dr Reddy's had partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and distribute the vaccine in India. In addition to the trials conducted in Russia by RDIF, phase II/III clinical trials of the vaccine were carried out by Dr Reddy's in India. In addition to the trials conducted in Russia by RDIF, phase II/III clinical trials of the vaccine were carried out by Dr Reddy's in India. Dr Reddy's said Sputnik V is now approved for use in 60 countries around the world. It ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators. Sputnik V uses two different vectors for the two shots in a course of vaccination. The efficacy of Sputnik V was determined to be 91.6 per cent as per a published article in the Lancet.

### Adani Green Energy's arm commissions 50 MW solar plant in Chitrakoot

Adani Green Energy subsidiary, Adani Solar Energy Chitrakoot One Ltd (ASECOL), has commissioned a 50 megawatt (MW) solar power plant in Chitrakoot, Uttar Pradesh. In a regulatory filing Adani Green Energy Ltd (AGEL) said the plant has a 25 years power purchase agreement with the Uttar Pradesh Power Corporation Ltd (UPPCL) at INR3.07/kwh. This commissioning takes AGEL's total operational renewable capacity to 3,520 MW, a step closer to its vision of 25 GW capacity by 2025. With the successful commissioning of this plant, AGEL has an operational solar generation capacity of over 3 GW. AGEL has a total renewable capacity of 15,240 MW including 11,720 MW that have been awarded and are at different stages of implementation. AGEL has a total renewable capacity of 15,240 MW including 11,720 MW that have been awarded and are at different stages of implementation. With this 50 MW, AGEL marks the beginning of this year's commissioning plan with full commitment from its team, amidst continuing challenges of the COVID-19 outbreak.

### Bank credit rise 5.56%; deposits 11.4% in FY21

Bank credit grew 5.56 per cent to INR109.51 lakh crore, while deposits rose 11.4 per cent to INR151.13 lakh crore in the financial year ended March 31, 2021, data released by the Reserve Bank of India (RBI) showed. In the 2019-20 fiscal, advances had grown at 6.1 per cent and deposits at 7.9 per cent. Though the interest rates of banks have reduced by 107 basis points from February 2020 to February 2021, the overall credit growth continued to moderate due to risk aversion and continued parking of excess liquidity with the RBI. In FY22, bank credit is likely to increase given the growth in the economy and the base effect coming into play. However, downside risks include lockdowns in key states, impacting the industry as well as the service segments.

### CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Quantum Digital Vision Ltd/India	Corporate meeting effective 14-04-2021
Shanti Educational Initiatives Ltd	Corporate meeting effective 14-04-2021
IFL Promoters Ltd	Corporate meeting effective 14-04-2021
KSB Ltd	Cash dividend of INR8.50 effective 15-04-2021
Filatex Fashions Ltd	Corporate meeting effective 15-04-2021
Par Drugs and Chemicals Ltd	Corporate meeting effective 15-04-2021
Bothra Metals & Alloys Ltd	Corporate meeting effective 15-04-2021
Finolex Industries Ltd	5 for 1 stock split effective 15-04-2021

### Domestic Events

- **Upcoming Result's:-** Infosys Ltd., Reliance Industrial Infrastructure Ltd., Tata Metaliks Ltd., Tinsplate Company of India Ltd., Wipro Ltd.
- **14th April 2021:-** India WPI Inflation for March 2021.

### Global Events

- **14th April 2021:-** The U.S. MBA Mortgage Applications for April 09, 2021., Euro Area Industrial Production for February 2021.
- **15th April 2021:-** The U.S. Initial Jobless Claims for April 10, 2021., The U.S. Retail Sales and Industrial Production for March 2021.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

### **Analyst Certification:**

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### **Terms & Conditions and Other Disclosures:**

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.



The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

**Sudipto Datta, Compliance Officer**

**SMIFS Limited.**

**Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.**

**Contact No.: +91 33 4011 5414 /91 33 6634 5414**

**Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com)**

**Website: [www.smifs.com](http://www.smifs.com)**